M&A Deal Summary |
|
---|---|
Date | 2016-06-23 |
Target | Imugen |
Sector | Test/Measurement Equipment |
Buyer(s) | Oxford Immunotec Global |
Deal Type | Add-on Acquisition |
Deal Value | 22M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 2002 |
Sector | Medical Products |
Employees | 260 |
Revenue | 74M USD (2019) |
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. The Company’s first product is the T-SPOT.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The T-SPOT.CMV test and the T-SPOT.PRT test are the Company’s second and third products and part of a series of products intended for the transplantation market. In addition to these three products, the Company has an additional six active development programs, each of which leverages our T cell, B cell and innate immune measuring technology. Oxford Immunotec Global was founded in 2002 and is based in Abingdon, the United Kingdom.
DEAL STATS | # |
---|---|
Overall | 2 of 3 |
Sector (Test/Measurement Equipment) | 1 of 1 |
Type (Add-on Acquisition) | 2 of 3 |
State (Massachusetts) | 1 of 2 |
Country (United States) | 2 of 3 |
Year (2016) | 1 of 2 |
Size (of disclosed) | 1 of 3 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2014-08-05 |
Boulder Diagnostics
Boulder, Colorado, United States Boulder Diagnostics is a private diagnostics company based in Boulder, Colorado that is developing immunology-based assays for rheumatology and infectious diseases. The primary focus of Boulder Diagnostics is on three products: Spirofind an assay to assist in the diagnosis of Lyme disease in both early and late-presenting forms, GoutifindTM an assay to assist in the diagnosis of Gout, obviating diagnosis by joint puncture, and StratokineTM an assay to help select biologics for autoimmune disease based on monitoring and prognosis of drug response. |
Buy | $8M |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2016-10-12 |
Immunetics
Boston, Massachusetts, United States Immunetics, Inc. is a diagnostics company focused on developing specialized tests for infectious diseases, such as Lyme disease. |
Buy | $6M |